 WALTHAM, Mass., March 03, 2022 GLOBE NEWSWIRE -- Viridian Therapeutics, Inc. NASDAQ: VRDN, a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2021, after the financial markets close on Thursday, March 10, 2022. 